List of Bendeka drug patents

Bendeka is owned by Eagle Pharms.

Bendeka contains Bendamustine Hydrochloride.

Bendeka has a total of 16 drug patents out of which 0 drug patents have expired.

Bendeka was authorised for market use on 07 December, 2015.

Bendeka is available in solution;iv (infusion) dosage forms.

Bendeka can be used as for the treatment of patients with chronic lymphocytic leukemia, for use in the treatment of patients with chronic lymphocytic leukemia and/or non-hodgkins lymphoma, for use in treatment of patients with chronic lymphocytic leukemia (cll) and/or non-hodgkin's lymphoma, for the treatment of patients with indolent b-cell non-hodgkin lymphoma; for the treatment of patients with chronic lymphocytic leukemia, for the treatment of patients with chronic lymphocytic leukemia; for the treatment of patients with indolent b-cell non-hodgkin lymphoma.

The generics of Bendeka are possible to be released after 15 March, 2033.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8791270 EAGLE PHARMS Bendamustine pharmaceutical compositions
Jan, 2026

(2 years from now)

US9572797 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(8 years from now)

US9265831 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(8 years from now)

US9572796 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(8 years from now)

US11103483 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(8 years from now)

US10010533 EAGLE PHARMS Formulations of bendamustine
Jan, 2031

(8 years from now)

US8609707 EAGLE PHARMS Formulations of bendamustine
Aug, 2031

(8 years from now)

US9572887 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(10 years from now)

US10052385 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(10 years from now)

US9579384 EAGLE PHARMS Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
Mar, 2033

(10 years from now)

US9000021 EAGLE PHARMS Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration
Mar, 2033

(10 years from now)

US9597397 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(10 years from now)

US9144568 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(10 years from now)

US9597399 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(10 years from now)

US9034908 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(10 years from now)

US9597398 EAGLE PHARMS Formulations of bendamustine
Mar, 2033

(10 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Dec 7, 2022

Drugs and Companies using BENDAMUSTINE HYDROCHLORIDE ingredient

Market Authorisation Date: 07 December, 2015

Treatment: For use in treatment of patients with chronic lymphocytic leukemia (cll) and/or non-hodgkin's lymphoma; For the treatment of patients with chronic lymphocytic leukemia; For the treatment of patients with indolent b-cell non-hodgkin lymphoma; For use in the treatment of patients with chronic lymphocytic leukemia and/or non-hodgkins lymphoma

Dosage: SOLUTION;IV (INFUSION)

How can I launch a generic of BENDEKA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic